NPS Receives Approval Letter From FDA

The Food and Drug Administration issued an approval letter to NPS Pharmaceuticals Inc. (NPSP) for its osteoporosis drug Preos while at the same time requesting more clinical information about an increase in the incidence of hypercalcemia in patients. Shares of the biotechnology company plummeted $5.27 to $8.77.